{
  "report_rows": [
    {
      "kpi": "Revenue (Q2'26)",
      "prediction": "BEAT",
      "answer": "pred ~$1.11B vs. cons ~$1.10B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Organic revenue growth (Q2'26)",
      "prediction": "IN-LINE",
      "answer": "pred ~7.5% vs. cons ~7.0%",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted EPS (Q2'26)",
      "prediction": "IN-LINE",
      "answer": "pred ~$0.33 vs. cons ~$0.33",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 organic growth framework",
      "prediction": "UNCHANGED",
      "answer": "guide ~7-8% organic +2-3% M&A vs. cons ~7-8% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY26 adj. earnings growth",
      "prediction": "UNCHANGED",
      "answer": "guide ~double-digit % vs. cons ~9-10% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adj. EBITDA margin (y/y)",
      "prediction": "UNKNOWN",
      "answer": "guide ~flat-to-slightly-down vs. cons ~+20-30bps y/y (Q2/2H2026)",
      "confidence": "LOW"
    }
  ],
  "day1_residual_pct": 1.5,
  "day1_confidence": "LOW",
  "day5_residual_pct": 2.0,
  "day5_path": "STABILIZE",
  "day5_rationale": "Deeply de-rated defensive (down ~33% from high, near 52-wk lows) into a low-expectations print; an in-line-to-slight-beat with the full-year 7-8% organic framework reaffirmed by the new CFO removes tail risk and supports a modest relief bounce, but lingering insurance/claims margin uncertainty and CFO-transition skepticism cap out-period estimate revisions, so the initial pop stabilizes rather than compounds. Downside if Q2 margins miss again like Q1 (the key credibility test) would flip this to a fade.",
  "day5_confidence": "LOW"
}